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Infections of humans and livestock with African trypanosomes are treated with drugs 23 
introduced decades ago that are not always fully effective and often have severe 24 
side effects. Here, the trypanosome haptoglobin-haemoglobin receptor (HpHbR) has 25 
been exploited as a route of uptake for an antibody-drug conjugate (ADC) that is 26 
completely effective against Trypanosoma brucei in the standard mouse model of 27 
infection. Recombinant human anti-HpHbR monoclonal antibodies were isolated and 28 
shown to be internalised in a receptor-dependent manner. Antibodies were 29 
conjugated to a pyrrolobenzodiazepine (PBD) toxin and killed T. brucei in vitro at 30 
picomolar concentrations. A single therapeutic dose (0.25 mg/kg) of a HpHbR 31 
antibody-PBD conjugate completely cured a T. brucei mouse infection within 2 days 32 
with no re-emergence of infection over a subsequent time course of 77 days. These 33 
experiments provide a demonstration of how ADCs can be exploited to treat 34 
protozoal diseases that desperately require new therapeutics. 35 
 36 
Author Summary  37 
Here we show that antibody-drug conjugates (ADCs) can be re-purposed from 38 
cancer immunotherapeutics to anti-protozoals by changing the specificity of the 39 
immunoglobulin to target a trypanosome cell surface receptor. Trypanosomes were 40 
used as a model system due to the availability of receptor null cell lines that allowed 41 
the unambiguous demonstration that ADCs targeted to a parasite surface receptor 42 
could be specifically internalised via receptor-mediated endocytosis. A single low 43 
dose of the resulting ADC was able to cure a stage 1 mouse model of trypanosome 44 
infection. We have used toxins and conjugation chemistry that are identical to anti-45 
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cancer ADCs demonstrating the ability to piggy-back onto the huge research efforts 46 
and resources that are being invested in the development of such ADCs.  47 
The potential for development of ADCs against a wide range of human pathogens is 48 
vast, where only epitope binding sites need vary in order to provide selectivity. This 49 
provides a far-reaching opportunity for the rapid development of novel anti-50 
protozoals for the targeted killing of a wide range of pathogens that cause disease 51 






















Infection with African trypanosomes causes disease in humans, livestock and wild 72 
animals. At least seven species are able to infect livestock but only Trypanosoma 73 
brucei subspecies normally infect humans: T. b. gambiense and T. b. rhodesiense 74 
cause chronic or acute Human African Trypanosomiasis (HAT) respectively (1). New 75 
drug treatments are required for human treatment, the drugs currently used require 76 
multiple administrations over periods of weeks and all can have severe side effects 77 
(reviewed in (2-4)).   78 
 79 
Without intervention, infection persists as the trypanosomes have evolved a 80 
population survival strategy based on antigenic variation of the variant surface 81 
glycoprotein (VSG) that is present as a densely packed coat on the external face of 82 
the plasma membrane. Receptors for host nutrient macromolecules are integrated in 83 
the VSG coat, such as the HpHbR which is involved in haem acquisition through 84 
binding and subsequent endocytosis of host haptoglobin-haemoglobin(5). Primate-85 
specific innate immune protein complexes have evolved to exploit this nutrient 86 
uptake and kill most isolates of T. brucei (5). The two complexes, Trypanolytic Factor 87 
1 and 2 (TLF1 and TLF2), each contain two primate-specific proteins, apolipoprotein 88 
L1 (apoL-1) (6) and haptoglobin-related protein bound to haemoglobin (HprHb) 89 
which acts as a molecular mimic of HpHb(7-10). HpHbR binds and internalises TLF1 90 
and the toxin apoL-1 kills the trypanosome (5, 11). Human infective trypanosomes 91 
have evolved counter-measures to the TLFs(12-19).  92 
 93 
The binding of a host macromolecule to a receptor, followed by the internalisation of 94 
the complex, provides a potential route to specifically deliver therapeutics into 95 
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trypanosome cells. Entry of TLF1 via the HpHbR and the release of a cytotoxin after 96 
internalisation is analogous to the mode of action of ADCs (20), a growing class of 97 
therapeutics, particularly used in applications in oncology(21-23) and also with 98 
demonstrated potential as anti-bacterials(24, 25). An early attempt to develop ADCs 99 
against the intracellular American trypanosome, Trypanosoma cruzi, used 100 
chlorambucil conjugated to polyclonal IgGs purified from chronically infected rabbits 101 
(26) and, while results were promising, this was only partially successful. More 102 
recently, antibody therapeutics against African trypanosomes based on single 103 
domain antibodies derived from camelid immunoglobulins (nanobodies) recognising 104 
some, but not all, VSGs (27, 28) have also been developed. One study used a 105 
nanobody apoL-1 fusion protein that was curative in mouse infections(29). In another 106 
two studies, nanobodies were used to create nanoparticles containing pentamidine, 107 
one of the current drugs used to treat trypanosome infection. These particles bound 108 
VSG and were successfully taken up into the endocytic pathway, the concentration 109 
required for cure was 10 to 100-fold lower than free pentamidine over a course of 110 
four doses (30, 31). However, the variability of the VSG molecules and underpinning 111 
antigenic variation will almost certainly limit their effectiveness as targets for 112 
therapeutic delivery.  113 
 114 
Here we have developed a recombinant human anti-trypanosome-HpHbR antibody 115 
conjugated to a PBD toxin, selected so that recognition of the trypanosome would be 116 
independent of the VSG identity. This approach also strategically exploits advances 117 
in anti-cancer ADC development. The antibody-PBD conjugate was effective at 118 
killing trypanosomes in culture at picomolar concentrations whereas killing of human 119 
cell lines required more than 100,000-fold higher concentrations. A single low dose 120 
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(0.25 mg/kg) of one of the ADCs resulted in a long-term cure in the standard mouse 121 
model of trypanosome infection(32, 33) with no apparent adverse effects.  122 
 123 
Results  124 
HpHbR was chosen as a target for ADCs for two reasons: first it is responsible for 125 
receptor mediated endocytosis of ligands larger than IgGs and structural information 126 
suggested it is accessible to external antibodies (34, 35); second, a cell line with 127 
both HpHbR alleles deleted (HpHbR -/-) was available as a control for specificity. 128 
HpHbR -/- cell lines have little or no growth phenotype in culture (5, 34), although 129 
they are attenuated in the murine experimental model of infection (5).  130 
 131 
Identification of single chain variable fragments recognising the N-terminal 132 
domain of the haptoglobin-haemoglobin receptor. 133 
In T. brucei, the mature HpHbR has a large N-terminal domain (264 residues) that 134 
contains the HpHb binding site (34) and a small C-terminal domain (79 residues) 135 
attached to the plasma membrane by a glycosylphosphatidylinositol anchor. 136 
Recombinant HpHbR N-terminal domain (34) was used for phage display affinity 137 
selection from a single chain variable fragment (scFv) library. Specificity for HpHbR 138 
was confirmed using phage ELISA and sixteen distinct scFvs were identified (Figure 139 
1A).  140 
 141 
HpHbR antibodies are internalised by receptor mediated endocytosis  142 
Six of the scFvs (S1 Figure) were reformatted as human IgG1 for further analysis. To 143 
determine whether any of these IgGs were endocytosed by trypanosomes in a 144 
receptor dependent manner, each was labelled with Alexa fluor-594 and incubated 145 
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with either Trypanosoma brucei, Lister 427, HpHbR wild-type or HpHbR -/- cells in 146 
culture for 2 hours in the presence of the lysosomal protease inhibitor FMK-024. A 147 
control IgG1 with an unrelated specificity (NIP228) was used in parallel. 148 
Internalisation was monitored by microscopy (Figure 2) and at 10 nM IgG1 five of the 149 
six HpHbR antibodies were endocytosed by wild-type cells but not by HpHbR-/- cells 150 
and localised to a compartment consistent with the lysosome. There was no 151 
internalisation of the control antibody in either cell line at 10 nM. Hence, five of the 152 
antibodies were internalised by receptor mediated endocytosis demonstrating that 153 
they recognised epitopes on HpHbR that are accessible on live cells. The sixth 154 
HpHbR antibody (Tb086) showed limited internalisation and was not used further.  155 
 156 
Toxin-conjugated HpHbR-targeting antibodies kill trypanosomes at picomolar 157 
concentrations 158 
The receptor-mediated endocytosis of these HpHbR antibodies was then exploited to 159 
assess the effectiveness of ADCs against T. brucei in vitro. Two PBDs, SG3199 and 160 
SG3552 (ref(36)) (Figure 1B), were used in these experiments; each was used as a 161 
toxin-linker derivative, SG3249 and SG3376 respectively (Figure 1B), for antibody 162 
conjugation. PBDs are DNA minor groove binding toxins (37-40) and were chosen as 163 
trypanosomes have a highly complex mitochondrial genome formed from a network 164 
of thousands of concatenated DNA circles and are consequently susceptible to DNA 165 
binding toxins. This sensitivity is illustrated by the original patent on ethidium 166 
bromide as a treatment for trypanosome infection and ethidium derivatives are still 167 




To assay for trypanocidal activity, cultures of T. brucei were incubated with a range 170 
of concentrations of the anti-HpHbR-PBD conjugates over 48 hours. Growth was 171 
measured as percentage proliferation compared to no treatment, with 0% relative to 172 
controls representing no viable cells observed, and IC50 values calculated. 173 
 174 
Initial experiments were designed to identify the most effective HpHbR antibody and 175 
used the PBD, SG3199. Free SG3199 had an IC50 of ~1 pM (Figure 3A, Table S1), 176 
this confirmed its toxicity towards trypanosomes and indicated that it is freely cell 177 
permeable. Prior to conjugation to the IgGs, SG3199 was modified by the addition of 178 
a linker to facilitate conjugation and release in the lysosome after proteolysis to 179 
produce SG3249(43) (Figure 1B). Free SG3249 had an IC50 of ~240 pM (Figure 3A, 180 
Table S1); presumably the hydrophilic nature of the linker meant that cell access via 181 
passive diffusion was reduced. Antibody-SG3249 conjugates were prepared for the 182 
five HpHbR antibodies selected in the uptake experiment above and the NIP228 IgG 183 
control, following IgG engineering to contain a surface exposed cysteine residue at 184 
position 239 in the heavy chain CH2 domain for conjugation to PBD molecules(44) 185 
(Figure 1B). The HpHbR antibody-SG3249 conjugates all killed trypanosomes with 186 
IC50 values between 9 and 86 pM compared to 2100 pM for the control NIP228-187 
SG3249 conjugate (Figure 3A and Table S1), demonstrating targeted cell killing by 188 
HpHbR antibody-PBD conjugates. The two most potent antibodies were Tb074 and 189 
Tb085 with IC50 values of 17 and 9 pM respectively and they were selected for 190 
further experiments. 191 
 192 
The next set of experiments used PBD SG3552 and its linker-derivative SG3376 (45, 193 
46) (Figure 1B). This toxin-linker combination was chosen as it was designed to have 194 
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fewer off-target effects (45, 47) and was shown to be more potent against 195 
trypanosomes in preliminary experiments. Three antibody-SG3376 conjugates were 196 
prepared from Tb074, Tb085 and NIP228 and all were tested for trypanocidal activity 197 
as above but using HpHbR wild type and -/- cell lines (Figure 3B and Table 1). 198 
SG3552 killed trypanosomes with IC50 values of 0.14 pM in wild type and 0.2 pM in 199 
HpHbR -/- cell lines; the addition of the linker to make SG3376 reduced the toxicity to 200 
112 pM and 197 pM in wild type and -/- cell lines respectively, again presumably due 201 
to the increase in hydrophilicity conferred by the linker reducing passive cell entry. 202 
The antibody conjugates Tb085-SG3376 and Tb074-SG3376 were effective in killing 203 
wild-type trypanosomes with IC50 values of 0.3 pM and 1.3 pM respectively. In 204 
contrast both were far less effective against HpHbR -/- cells with IC50 values of 1390 205 
pM and 3270 pM showing that the action of the ADC is dependent on HpHbR 206 
expression. The action of the NIP228-SG3376 conjugate was unaffected by HpHbR 207 
expression and had an IC50 of 3750 pM and 3000 pM in HpHbR wild type and -/- 208 
cells respectively.  Taken together these findings showed that HpHbR antibody-209 
SG3376 conjugates are highly effective in killing trypanosomes through a 210 
mechanism whereby the presence of the receptor increases specificity by several 211 











IC50  (pM) 
Cell line 
T. b. brucei T. b. brucei 
HpHbR -/- 
Human Jurkat 
    
SG3552 0.14 0.195 19.6 
Toxin (0.11-0.18) (0.14-0.27) (10.8-35.8) 
   
 SG3376 112 197 >50,000 
Toxin plus linker (76.7-163) (145-268) 
 
    NIP228-SG3376 3750 3000 >50,000 
Control  (2610-5380) (2260-3960) 
 




    Tb085-SG3376 0.297 1390 >50,000 
 
(0.25-0.36) (1030-1880) 
  220 
Table 1: IC50 values (pM) of SG3552-based toxins and ADCs against T.brucei 221 
cell lines and a human Jurkat cell line. The IC50 values of toxin SG3552, toxin plus 222 
linker SG3376, a control ADC (NIP228-SG3376) and two anti-trypanosome ADCs 223 
targeting the T. b. brucei HpHbR (Tb074-SG3376 and Tb085-SG3376) against T. b 224 
brucei wild type and T. b brucei HpHb -/- (Figure 3B) were calculated. Values in bold 225 
are best-fit IC50 values, the range is the 95% confidence intervals. It was not possible 226 
to calculate accurate IC50 values for the Jurkat cell line due to lack of saturation of 227 
the cell killing assay and so all were conservatively estimated as greater than 50 nM 228 
from the data in S2 Figure. All values are shown to 3 significant figures.  229 
 230 
To assess whether the HpHbR antibody-SG3376 conjugates have specificity for 231 
trypanosomes over mammalian cells in culture, PBD toxin SG3552 and antibody-232 
SG3376 conjugates were assessed for toxicity against a range of human cell lines. 233 
SG3552 was toxic to all cell lines assayed at picomolar concentrations (S3 Figure), 234 
the most sensitive was the Jurkat cell lines with an IC50 value of 19.6 pM, around 235 
100-fold less-sensitive than the T. brucei cell lines (Table 1). This was expected: 236 
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trypanosomes are particularly sensitive to many DNA damaging toxins as described 237 
above. The NIP228-SG3376, Tb074-SG3376 and Tb085-SG3376 conjugates all had 238 
IC50 values that were conservatively estimated to be >50 000 pM (S3 Figure). The 239 
IC50 values of the two HpHbR antibody-SG3376 conjugates for the human cell lines 240 
was at least 50,000 times greater than those for trypanosomes (Table 1). 241 
 242 
A single Tb085-SG3376 administration results in the clearance of trypanosome 243 
infection in mice 244 
Based on the specificity and potency observed in the above experiments, Tb085-245 
SG3376 conjugate was chosen to determine anti-HpHbR-toxin conjugate efficacy in 246 
a mouse model of T. b. brucei infection. Mice were infected with a pleomorphic 247 
trypanosome cell line, T. b. brucei GVR35-VSL2, that expresses a luciferase 248 
transgene (PpyRE9h) to facilitate measurement of infection in live animals over a 249 
prolonged time course using bioluminescence imaging (BLI) (32, 33). This method 250 
has the advantage that it detects trypanosomes in the bloodstream and tissues. 251 
Fifteen mice were infected with trypanosomes and imaged on day 3 post infection to 252 
provide a pre-treatment BLI signal level indicative of the whole-body infection burden 253 
measured as photons per second (p/s) after administration of luciferase substrate. 254 
All infected mice had a total flux of between 2.5x109 and 5.9x109 p/s with the 255 
exception of a single mouse which had a lower level of infection at 3x107 p/s. 256 
Subsequent to imaging, on day 3, groups of five mice were then treated with (1) 0.25 257 
mg/kg Tb085-SG3376 or (2) 0.25 mg/kg NIP228-SG3376 or (3) PBS alone. Three 258 




Infection levels were assessed by BLI on days 4, 5, 6 and 7, and then at regular 261 
further time points (Figure 4, S4 Figure, S5 Figure). Within the first day post-262 
treatment the BLI signal in Tb085-SG3376-treated mice had dropped 3-fold relative 263 
to the pre-treatment signal whilst control mice (NIP228-SG3376 or PBS alone) had 264 
increased more than 2-fold. These control mice remained infected with a BLI signal 265 
consistent with a first and second wave of parasitaemia, characteristic of 266 
trypanosome infection dynamics (48, 49). At day 14 (11 days post-treatment), control 267 
mice were culled at a humane endpoint, as the BLI signal represented a parasite 268 
burden that would invariably lead to clinical symptoms of trypanosomiasis and death 269 
(33). 270 
 271 
In contrast, the BLI signal in mice in group 1 (treated with Tb085-SG3376) had 272 
decreased to the level of uninfected controls by 2 days post-treatment. The BLI 273 
signal remained indistinguishable from the uninfected controls for 60 days post-274 
treatment and the mice continued to appear healthy throughout the experiment, not 275 
showing any external symptoms of clinical trypanosomiasis. To determine if Tb085-276 
SG3376 treated mice were harbouring very small numbers of trypanosomes that 277 
were kept in check by the mouse adaptive immune response, the mice were 278 
immunosuppressed with a single dose of cyclophosphamide on day 66 post-infection 279 
and BLI measurements made on days 69, 74, 76 and 80 post-infection; no 280 
trypanosomes were detected (Figure 4, S4 Figure, S5 Figure). On day 80 post-281 
infection mice were culled and BLI was performed on mouse tissues post-necropsy; 282 
again no trypanosomes were detected in any tissue (S6 Figure). Finally, both a blood 283 
sample and a section of brain tissue from each of the five mice treated with Tb085-284 
SG3376 were incubated in trypanosome culture medium for one month; in no case 285 
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were any trypanosomes then detected. Together, these observations and 286 
measurements indicate that a single dose of Tb085-SG3376 was sufficient to cure 287 
infection in 5/5 mice in the experimental group. 288 
 289 
Discussion 290 
African trypanosomes proliferate in the bloodstream and tissue spaces of their 291 
mammalian hosts where they are continually exposed to the adaptive immune 292 
response. The trypanosome cell surface is covered by a densely packed coat of 293 
VSG that underpins persistence of infection by antigenic variation. The VSG coat 294 
must be permissive for receptor mediated endocytosis of host macromolecules as 295 
nutrients and here this has been exploited for the delivery of an ADC. The HpHbR 296 
was chosen for this study as: (i) it is a natural route for uptake of the trypanolytic 297 
factors(5), which kill sensitive trypanosomes strains in human serum; (ii) it is 298 
accessible to ligands larger than IgG (5); (iii) it has a known structure (34, 35);  (iv) 299 
HpHbR null cell lines grow at a normal rate in culture (5, 34) and were an ideal 300 
control for specificity of uptake. We found that HpHbR monoclonal antibodies are 301 
taken up into HpHbR wild type cells but not HpHbR -/-cells, proving that receptors for 302 
host macromolecules are accessible on live trypanosomes.  These same antibodies 303 
conjugated to a PBD were able to kill trypanosomes in culture at pM concentration in 304 
a manner that was dependent on HpHbR expression. Significantly higher doses, 305 
were needed to kill a panel of mammalian cell lines. Finally, in the mouse model of 306 





The findings here have validated an approach that builds on the considerable 310 
progress in anti-cancer ADCs and repurposing into an anti-protozoal simply involves 311 
the development of pathogen specific antibodies. The use of ADCs here was 312 
specifically based on those developed in oncology. Currently, ADCs are used in the 313 
clinic against Hodgkin lymphoma (Brentuximab vedotin) (22) and HER2-positive 314 
breast cancer (ado-trastuzumab-emtansine) (50). Many others are in pre-clinical 315 
development or clinical trials, including ADCs against a range of cancers that 316 
incorporate PBDs, including SG3249, one of the toxins used in this study (51-53).  317 
 318 
The success of the experiments above lead to the question of whether this is a 319 
realistic approach for development of therapeutics for trypanosome and other 320 
protozoan infections. Amongst the key challenges in generating ADCs for 321 
applications in oncology is ensuring minimal off-target toxicity and so, as well as 322 
through ADC chemistry, low doses are desirable (reviewed in (54)). The single dose 323 
of 0.25 mg/kg was selected in these experiments as a proof-of-concept because it is 324 
at the lower end of effective oncological ADC treatment in mice(55) and is well below 325 
the anticipated maximum tolerated dose (56). The minimum efficacious dose 326 
achievable with the anti-HpHbR ADC was not tested in this study and it is likely that 327 
the targeting of parasites will be achieved using lower doses than required for 328 
oncology for two key reasons. First, in contrast to the surface of cancer cells, 329 
parasite-specific surface receptors are entirely different from host cell surface 330 
receptors leading to highly selective uptake of the antibody into the pathogen. 331 
Second, the effectiveness of the ADC in this study was enhanced by the sensitivity 332 
of trypanosomes to DNA-binding agents, in comparison to host cells. Together these 333 
led to a 100,000-fold difference in toxicity between trypanosome and human cells in 334 
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vitro. These considerations will also apply to other protozoal pathogens providing a 335 
suitable target can be identified. 336 
 337 
Disease caused by T. brucei infection has two stages: in stage 1 trypanosomes are 338 
excluded from the central nervous system (CNS) by the blood brain barrier (BBB) 339 
while in stage 2 infections trypanosomes enter the CNS. In the experimental model 340 
used here, we have tested the ability to clear a stage 1 infection. Would ADCs be 341 
able to target trypanosomes in the CNS? While administered intravenous antibodies 342 
are present in the CNS at less than 0.1% of the concentration in the blood in murine 343 
models (57, 58) increased BBB permeability has been observed in murine models of 344 
neurological-stage trypanosomiasis (59-61), which will increase the CNS 345 
concentration of administered antibodies. Further, bifunctional fusion antibodies that 346 
can cross the blood-brain barrier have been reported (57). 347 
 348 
It is worth contrasting a potential ADC treatment with the current effective drug 349 
regimens for trypanosomiasis. Pentamidine, the current stage 1 T. b. gambiense 350 
treatment, is administered to patients intramuscularly at 4 mg/kg over 7 days, 351 
although it has been shown to clear a mouse model of T. b. brucei infection at 2.5 352 
mg/kg over four intraperitoneal injections (30, 62). For stage 2 T. b. gambiense 353 
infection, the current nifurtimox eflorithine combination therapy involves oral 354 
nifurtimox 15 mg/kg/day for 10 days plus eflornithine infusions 400 mg/kg/day for 7 355 
days (for a 50 kg adult this is 20 g eflornithine per day) (63). A single dose of ADC 356 




Considerable resources are being used for the optimisation, assessment and clinical 359 
trials of oncology ADCs. It is difficult to imagine such resources being available for 360 
the developmental pipeline of therapeutics against protozoal pathogens that primarily 361 
affect developing countries. Both cancer and protozoal pathogens are eukaryotic 362 
cells and so the oncology-based strategies that take advantage of the cell biology of 363 
cancer cells are often applicable to protozoa. Therefore, the scope for benefiting 364 
from oncology developments is clear, particularly where the drug (such as PBDs, as 365 
used in this study) do not deviate from oncology ADCs that are under development. 366 
If simply modifying the epitope binding site can allow anti-cancer ADCs to be 367 
repurposed then they could realistically be developed as a novel class of 368 
therapeutics for protozoan pathogens. The cell surfaces of protozoan pathogens are 369 
often particularly well studied due to the biological interest in their role in 370 
host:parasite interactions and therefore the literature contains a reservoir of potential 371 
targets (for example (64-68)). It is also worth noting that the production cost of ADCs 372 
is far less than often realised (69-73). 373 
 374 
In summary, we have demonstrated that a single dose of an ADC, shown to 375 
specifically operate through the HpHbR was able to completely cure an infection in a 376 
stage 1 trypanosomiasis model. These type of agents have the potential for 377 
development for use to treat trypanosome infection in humans, and in the longer 378 
term livestock animals. Furthermore, this work illustrates that developments in 379 
oncology ADCs can be applied to protozoal pathogens, the causal agents of many 380 





Materials and Methods 384 
Phage display selection of anti-HpHbR N-terminal domain single chain variable 385 
fragments 386 
Recombinant HpHbR N-terminal domain (NTD) was expressed as previously 387 
described (34) and a scFv antibody library was used to perform soluble and panning 388 
phage display selections (74). Briefly, panning selections were performed by coating 389 
5 µg/mL biotinylated HpHbR NTD on to a single well of a streptavidin-coated 96-well 390 
plate or 10 µg/mL non-biotinylated HpHbR NTD on to a single well of a Nunc 391 
Maxisorp plate overnight at 4oC. Coated wells were washed three times with 392 
phosphate buffered saline (PBS) prior to incubation for 1hr at room temperature with 393 
3% Marvel skimmed milk powder in PBS. Next, 1 x 1012 phage particles in 6% Marvel 394 
in PBS were added to each coated well and incubated for 1hr at room temperature. 395 
The wells were washed five times with PBS containing 0.1% Tween-20 and five 396 
times with PBS prior to elution and recovery of phage. For soluble selection, phage 397 
were pre-incubated with magnetic beads in 3% Marvel in PBS at room temperature 398 
for 1 hour. Subsequently, the magnetic beads were removed and the phage-399 
containing supernatant was incubated with biotinylated HpHbR NTD at room 400 
temperature for 1 hour. Streptavidin magnetic beads were subsequently added to the 401 
reaction and incubated at room temperature for 5 minutes. The magnetic beads were 402 
washed five times with 0.1% Tween-20 in PBS. For all selections, phage were eluted 403 
with 10 µg/ml trypsin in PBS for 30 minutes at 37oC. Exponentially grown TG1 E.coli 404 
cells were infected with the eluted phage and grown overnight at 30oC on agar plates 405 
containing ampicillin.  E. coli colonies were harvested from the bioassay plates and 406 
phage particles were rescued by super-infecting with M13 KO7 helper phage and 407 
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used in the next round of selection. In total, three serial rounds of selection were 408 
performed. 409 
 410 
Phage ELISA 411 
Individual phage were produced from E. coli and assayed, by phage ELISA, against 412 
TbHpHbR NTD in parallel with BSA and streptavidin. Briefly, 10 µg/ml of each 413 
protein was coated onto Nunc Maxisorp plates and 5µg/mL of each biotinylated 414 
protein was coated onto streptavidin-coated plates overnight at 4oC. Plates were 415 
washed three times with PBS before being incubated with 3% Marvel in PBS for 1 416 
hour at room temperature. Phage containing supernatants were blocked with an 417 
equal volume of 6% Marvel in 2xPBS for 1 hour at room temperature. Coated plates 418 
were washed three times with PBS and incubated with 50 l of blocked phage 419 
supernatants for 1hr at room temperature. Plates were washed three times with 420 
0.1% Tween 20 in PBS and bound phage were detected using an anti-M13 421 
horseradish peroxidase conjugated antibody and colorimetric substrate. Rabbit 422 
polyclonal anti-TbHpHbR antibody was used as a positive control and detected with 423 
mouse anti-rabbit IgG HRP. 424 
 425 
Generation of full length human IgG1 and THIOMABS 426 
Selected scFvs were converted to full length human IgG1s using standard molecular 427 
biology techniques. Plasmids encoding secreted antibody (75) were purified by 428 
protein A affinity chromatography. Recombinant antibody was labelled with Alexa 429 
Fluor 594 following the manufacturer’s instructions (Life technologies). Standard 430 
molecular biology techniques were used to introduce a cysteine residue at position 431 
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239 in the CH2 domain of each heavy chain (44).  Recombinant THIOMABs were 432 
expressed and purified as detailed for full length IgG1.  433 
 434 
PBD conjugation to THIOMABs 435 
The HpHbR THIOMABS and a NIP228 negative control were reduced by the 436 
addition of a forty fold molar excess of tris(2-carboxyethyl)phosphine (TCEP) in PBS, 437 
1 mM EDTA, pH 7.2 for 4 h at 37oC.  TCEP was subsequently removed and the 438 
THIOMABS were re-oxidised with a twenty times molar excess of dehydroascorbic 439 
acid for 4h at 25oC. A ten times molar excess of toxin plus linker was added and 440 
incubated for 1 h at 25 oC, the reactions were quenched by the addition of excess of 441 
N-acetyl-L-cysteine. The resultant ADCs were formulated in PBS, pH 7.2 after 442 
ultrafiltration to removed excess toxin.  ADCs were characterized by determination of 443 
monomeric purity by size exclusion chromatography (Table S2), drug-antibody-ratio 444 
(DAR) by RP-HPLC chromatography (Table S2) and molecular mass (by LC-MS of 445 
the reduced ADCs) (S5 Figure) 446 
 447 
Trypanosome cell culture 448 
T. b. brucei Lister 427 bloodstream cells were grown in HMI-9 salts plus 10% foetal 449 
calf serum (FCS) at 37°C with 5% CO2 (76). The T. b. brucei Lister 427 HpHbR -/- 450 
cell line used here has been described previously (34). 451 
 452 
Internalisation of fluorescently labelled IgGs into live cells 453 
For T. b. brucei uptake assays 1 x 106 cells per assay were incubated with 10 nM 454 
Alexa Fluor 594-labelled IgG in 300µl HMI-9, 10% FCS, 2µM FMK-024 protease 455 
inhibitor for 1.5 hours at 37°C. Cells were washed once in HMI-9, 10% FCS then 456 
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fixed in 1% PFA for 10 minutes at room temperature and resuspended in PBS. 457 
Internalisation was determined by microscopy using a Zeiss Imager M1 microscope 458 
and analysed with AxioVision Rel 4.8 software. 459 
 460 
In vitro trypanosome cell-killing assays  461 
T. b. brucei Lister 427 wild-type or HpHbR -/- cell lines were incubated at 1 x 104 462 
cells/ml in triplicate with PBDs or ADCs for 48 hours before cells were counted and 463 
growth was calculated relative to an untreated control for each cell line. All assays 464 
contained 0.5% DMSO. Data were Log10 transformed and nonlinear regression lines 465 
of best fit and IC50 values were calculated using GraphPad Prism 6.  466 
 467 
CellTiter-Glo Luminescent Cell Viability Assay 468 
In vitro viability cell assays were performed with primary and transformed human cell 469 
lines: Raji (ECACC), Jurkat E6.1 (ATCC), NHLF (LONZA) and HUVEC (LONZA).  470 
These cell lines were mycoplasma tested and authenticated by PCR using human 471 
16-marker short tandem repeat profiling and interspecies contamination test by 472 
IDEXX (Columbia, MO). Cells seeded at 2 x 105 cell/ml (Raji and Jurkat) and at 2 x 473 
103 cell/ml (NHLF and HUVEC) in 96 well plates were incubated with the SG3552 474 
toxin, the toxin+linker SG3376 and the corresponding ADCs (Tb074-SG3376, 475 
Tb085-SG3376 and NIP228-SG3376). All assays contained 0.5% DMSO. After 96 476 
hours, the number of viable cells in culture was measured using the CellTiter-Glo 2.0 477 
luminescent cell viability assay and read in Envision plate reader. Growth was 478 
calculated relative to an untreated control for each cell line. Data were Log10 479 
transformed and nonlinear regression lines of best fit and IC50 values were 480 




Mouse infection and bioluminescent imaging of trypanosome infection 483 
Pleomorphic T. b. brucei GVR35-VSL2 bloodstream forms were cultured and 484 
maintained at 37°C/5%CO2 in HMI-9 medium supplemented with 20% FBS, 1μg/ml 485 
puromycin and 1% methyl cellulose (33). Parasites were maintained at <1 x 106 ml-1 486 
and were not cultured for more than three passages prior to mouse infection. 487 
 488 
Mice were purchased from Charles River (UK). They were maintained under specific 489 
pathogen-free conditions in individually ventilated cages with a 12 hour light/dark 490 
cycle and access to food and water ad libitum. Female BALB/c mice aged 8 to 12 491 
weeks were infected intraperitoneally with 3x104 T. b. brucei GVR35-VSL2 cells (33). 492 
Three groups of five mice were infected. On day 3 post infection the mice were 493 
imaged to obtain the pre-treatment infection level. Five mice received 0.25 mg/kg 494 
Tb085-SG3376, five mice received PBS alone and five mice received 0.25 mg/kg 495 
NIP288, all intravenously. A group of three mice was not infected.  496 
 497 
Imaging was carried out by intraperitoneal injection of 150 mg/kg D‐luciferin. After 5 498 
minutes, mice were anaesthetised with 2.5% (v/v) gaseous isofluorane in oxygen. 499 
The mice were transferred to the IVIS Illumina and imaged using LivingImage 4.3. 500 
software (PerkinElmer). Exposure times were determined automatically and varied 501 
between 0.5 s and 5 min depending on the radiance. After imaging, mice were 502 
allowed to recover and transferred back to their cages.  503 
 504 
At 66 days post-infection, Tb085-SG3376 treated mice were immunosuppressed 505 
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Figures Legends 731 
 732 
Figure 1: The generation of ADCs that target the T. brucei HpHbR.   733 
(A) Workflow for the generation of anti-trypanosomal ADCs. (B) Structures of the two 734 
PBD toxins (SG3199 and SG3552) and their corresponding toxins plus linker 735 
derivatives (SG3249 and SG3376) used in this study. Note that the linker of SG3249 736 
contains a cleavable dipeptide motif whereas the linker of SG3376 does not. 737 
 738 
Figure 2: Receptor mediated endocytosis of humanised anti-HpHbR IgG1s. 739 
Uptake of Alexa594-labelled antibodies into T. b. brucei Lister 427 HpHbR wild type 740 
and -/- cells was monitored by microscopy. Uptake of five of the seven selected 741 
antibodies was detected at 10 nM in wild-type (indicated by arrows in upper panel) 742 
but not in HpHbR -/- cells (lower panel). No specific uptake of the remaining antibody 743 




Figure 3: HpHbR antibody-PBD conjugates result in T. brucei cell death at low 746 
picomolar concentrations in vitro in a HpHbR-dependent manner. 747 
(A) Toxin SG3199 kills T. b. brucei wild type cells at sub-picomolar concentrations 748 
(IC50 0.86 pM), killing activity is reduced by the addition of a linker (SG3249 IC50 749 
236.0 pM). Conjugation of SG3249 to a non-specific control antibody (NIP228) 750 
further reduces trypanosome killing activity to low nanomolar concentrations (IC50 2.1 751 
nM) whereas conjugation of SG3249 to antibodies that target the HpHbR increased 752 
killing activity to low picomolar concentrations (IC50 values range from 86 pM for 753 
Tb073-SG3249 to 9.4 pM for Tb085-SG3249). All assays were carried out in 754 
triplicate over 48 hours. Lines represents nonlinear regression lines of best fit on 755 
Log10 transformed data. Error bars represent standard error of the mean (s.e.m.), 756 
n=3 biological replicates (carried out in parallel). (B) Toxin SG3552 kills T. b. brucei 757 
wild type and HpHbR -/- cells with sub-picomolar IC50 concentrations The IC50 is 758 
increased by orders of magnitude by the addition of a linker (Table 1). Conjugation of 759 
SG3376 to a non-specific control antibody (NIP228) further increases the IC50 to 760 
nanomolar concentrations in both trypanosome cell lines. HpHbR antibody SG3376 761 
conjugates have an IC50 in the low/sub picomolar range for wild type T. b. brucei. In 762 
contrast, IC50 values with T. b. brucei HpHbR -/- cells remained similar to the control 763 
ADC. All assays were carried out in triplicate over 48 hours. Lines represents 764 
nonlinear regression lines of best fit on Log10 transformed data. See Table 1 for 765 
corresponding IC50 values. Error bars represent s.e.m., n=3 biological replicates 766 
(carried out in parallel). 767 
 768 
Figure 4: A single low dose of Tb085-SG3376 was able to cure infection in a 769 
mouse model of trypanosomiasis.  770 
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Three groups of 5 mice were infected with pleomorphic T. b. brucei GVR35-VSL2 771 
cells (32, 33), which allow for parasite burden in live mice to be assessed over a time 772 
course by bioluminescent imaging (BLI). BLI was performed prior to any treatment at 773 
3 dpi and then at regular time points following treatment on 3 dpi with a single 774 
intravenous dose of (1) 0.25 mg/kg Tb085-SG3376 (n=5), (2) 0.25 mg/kg NIP228-775 
SG3376 (n=5) or (3) PBS alone (n=5). Unlike the control-treated mice, Tb085-776 
SG3376 treatment caused a decrease in the luminescent signal to that obtained from 777 
uninfected control animals within 2 days and this remained the case for the duration 778 
of the infection, including following the immunosuppression of Tb085-SG3376 779 
treated mice at 66 dpi. Mice treated with NIP228-SG3376 or PBS were culled at a 780 
humane endpoint on day 14.  (A) Quantification shown is the combined (dorsal + 781 
ventral) luminescence over the whole mouse in photos per second (p/s). The 782 
corresponding quantification data from the 18 individual mice are shown in S5 783 
Figure. Error bars represent standard deviation. Downward error bars are missing 784 
from 4 data points due to scale constraints. (B) For each group of mice selected 785 
ventral images for the BLI are shown. Corresponding dorsal images of the same 786 
mice are shown in S4 Figure. The scale bar represents the photons emitted at any 787 
given point on the image. Exposure times range from 0.5 seconds (for heavily 788 
burdened mice) to 5 minutes (for uninfected animals). One mouse in the PBS control 789 
group had a lower BLI signal than all other infected mice at 3 dpi (S5 Figure). In the 790 
image shown here this mouse appears negative, however, this is due to the low 791 






Supporting information Figure Legends 796 
 797 
S1 Figure: Sequences of the six scFv targeting the HpHbR NTD. The framework 798 
domains (FW) are shown in black and the complementarity-determining regions 799 
(CDR1-3) are shown in blue. Sequence variation between scFvs is in CDR3, as 800 
annotated by grey boxes.  801 
 802 
S2 Figure: Conjugating toxin SG3552 to antibodies that recognise the T. brucei 803 
HpHbR reduces toxicity against human cell lines. Toxin SG3552, toxin plus linker 804 
SG3376 and the associated ADCs were incubated with (A) Jurkat T-cells, (B) Human 805 
Umbilical Vein Endothelial Cells (C) Normal Human Lung Fibroblasts, and (D) Raji B-806 
cell lymphoma cells in FCS. Toxin SG3552 kills the human cell lines at picomolar 807 
concentrations. Killing activity is reduced in all cell lines by the addition of the linker 808 
(SG3376) or incorporation into a control or Anti-HpHbR ADC (NIP22-SG3376, 809 
Tb074-SG3376, Tb085-SG3376) to mid-to-high nanomolar concentrations. Lines 810 
represents nonlinear regression lines of best fit on Log10 transformed data, although 811 
it was not possible to fit accurate lines or calculate IC50 values for the ADCs due to 812 
lack of saturation of the cell killing assay. All assays were carried out in triplicate over 813 
96 hours. Error bars represent s.e.m., n=3. 814 
 815 
S3 Figure: Mass Spectrometry analysis of SG3376-containing antibody-toxin 816 
conjugates. Mass spectrometry analysis of reduced antibody-toxin conjugates was 817 
performed using a RSLC UPLC system coupled to an Exactive EMR Orbitrap MS. L0 818 
= unconjugated light chain species, H0 = unconjugated heavy chain species, H1 = 819 




S4 Figure: Bioluminescent imaging of T. b. brucei infected mice before and 822 
after treatment with antibody-toxin conjugates.  823 
Parasite burden in mice infected with pleomorphic T. b. brucei GVR35-VSL2 cells 824 
was assessed by BLI following intraperitoneal injection of d‐luciferin. BLI was 825 
performed prior to any treatment at 3 days post infection (dpi) and then at regular 826 
time points following treatment on 3 dpi with (1) Tb085-SG3376 (n=5), (2) NIP228-827 
SG3376 (n=5) or (3) PBS alone (n=5), with selected time points shown here. 828 
Uninfected mice were imaged as controls (n=3). Treatment with Tb085-SG3376 829 
decreased the luminescent signal to that obtained from uninfected control animals 830 
within 2 days and this remained the case for the duration of the infection, including 831 
following the immunosuppression of Tb085-SG3376- treated mice at 66 dpi.  832 
For each group of mice both the dorsal and ventral images are shown. Scale bar 833 
represents the photons emitted at any given point on the image. Exposure times 834 
range from 0.5 seconds (for heavily burdened mice) to 5 minutes (for uninfected 835 
animals). One mouse in the PBS control group had a lower BLI signal than all other 836 
infected mice at 3 dpi (S5 Figure). In the image shown here this mouse appears 837 
negative, however, this is due to the low exposure time required for adjacent mice. 838 
Quantification of the total luminescence from each mouse was also carried out 839 
(Figure 4 and S5 Figure).  840 
 841 
S5 Figure: A single low dose of Tb085-SG3376 was able to cure infection in a 842 
mouse model of trypanosomiasis: data from individual mice. 843 
Three groups of 5 mice were infected with pleomorphic T. b. brucei GVR35-VSL2 844 
cells, which allow for parasite burden in live mice to be assessed over a time course 845 
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by bioluminescent imaging (BLI). BLI was performed prior to any treatment at 3 dpi 846 
and then at regular time points following treatment on 3dpi with a single intravenous 847 
dose of (1) 0.25 mg/kg Tb085-SG3376 (n=5), (2) 0.25 mg/kg NIP228-SG3376 (n=5) 848 
or (3) PBS alone (n=5). Unlike the control-treated mice, Tb085-SG3376 treatment 849 
caused a decrease in the luminescent signal to that obtained from uninfected control 850 
animals within 2 days and this remained the case for the duration of the infection, 851 
including following the immunosuppression of Tb085-SG3376 treated mice at 66 dpi. 852 
Mice treated with NIP228-SG3376 or PBS were culled at a humane endpoint on day 853 
14.  Quantification shown is the combined (dorsal + ventral) luminescence over the 854 
whole mouse in photos per second (p/s). The combined quantification data from the 855 
4 groups of mice are shown in Figure 4. Selected images for the BLI are shown in S5 856 
Figure.  857 
 858 
S6 Figure: No parasites were detected by BLI post-necropsy in T. b. brucei 859 
infected mice following treatment with Tb085-SG3376. The five mice that were 860 
infected with pleomorphic T. b. brucei GVR35-VSL2 cells, treated with 0.25 mg/kg 861 
Tb085-SG3376 (3 dpi) and immunosuppressed (66 dpi) were culled at 80 dpi. Post-862 
necropsy, mice corpses and selected organs were assessed by BLI. Consistent with 863 
BLI data from live mice, BLI signal was equivalent to the uninfected control mice.  864 
 865 
S1 Table: IC50 values (pM) of SG3199-based toxins and antibody-toxin 866 
conjugates against wild type T. b. brucei. The IC50 values of toxin SG3199, toxin 867 
plus linker SG3249, a control ADC (NIP228-SG3249) and five anti-trypanosome 868 
antibody toxin conjugates targeting the T. brucei HpHbR (Tb017-SG3249, Tb073-869 
SG3249, Tb074-SG3249, Tb078-SG3249, Tb085-SG3249) were calculated against 870 
33 
 
T. b brucei wild type (Figure 3). Values in bold are best-fit IC50 values, the range is 871 
the 95% confidence intervals. All values are shown to 3 significant figures.  872 
 873 
S2 Table: Monomer content and drug-antibody-ratio (DAR) of SG3376-874 
containing Antibody-toxin conjugates. Monomeric purity was determined by size 875 
exclusion chromatography (SEC) and the DAR was determined by RP-HPLC. Both 876 
assays were performed on a Shimadzu Nexera UPLC system fitted with a Shimadzu 877 



















































Figure 3 923 
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% HMW % 
Monomer 
% LMW 
NIP228-SG3376 3.2 90.1 6.7 1.77 
Tb074-SG3376 5.4 92.1 2.5 1.80 
Tb085-SG3376 0 100 0 1.79 
 997 
S2 Table 998 
 999 
